HTGF backs Immunservice’s series-C

The fresh funding will be used to develop the company's biological immunotherapy methods. The consortium of previous investors comprises the Hubertus Wald Foundation and two business angels.

HTGF injects up to €2m worth of growth financing into its portfolio companies.

Previous funding
HTGF injected seed financing into Immunservice in January 2008. The capital was earmarked for industrial-scale production of its lead product, Pulmoleukin, and for the preparation of the approval process.

Company
Headquartered in Hamburg, Immunservice develops medicines that activate the body's own immune system to eliminate cancer and viral infections. The biotechnology firm focuses on renal cancer, lung tumours and melanoma. The company was founded in 2006.

People
Edith Huland is CEO of Immunservice. Michael Brandkamp is CEO of HTGF.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Germany
• High-Tech Gründerfonds